EUVIMEDEUVIMED entdecken
Crossref

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index

Mara Persano iD, Margherita Rimini iD, Francesca Salani iD, Federica Lo Prinzi, Federico Nichetti, Anna Saborowski, Lorenzo Antonuzzo, Laura Passeri, Tomoyuki Satake, Frederik Peeters, Caterina Vivaldi, Tiziana Pressiani und 48 weitere

Liver International · 2025-07 · 45 (7)

DOI: 10.1111/liv.70181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 17.06.2025. Verfasst von Mara Persano und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Over the years, prognostic indexes have been developed to help clinicians stratify patients with biliary tract cancers (BTC) into risk groups. This study aims to identify a new prognostic index for patients with BTC treated with cisplatin, gemcitabine and durvalumab (CGD) in the first‐line setting. Patients and Methods The study population consisted of patients with BTC from 11 Eastern and Western Countries. Using multivariate analysis for overall survival (OS), we identified 5 baseline statistically significant variables: stage, carcinoembryonic antigen (CEA) levels, albumin levels, gamma glutamyl transferase (GGT) levels, neutrophil‐to‐lymphocyte ratio (NLR). Metastatic disease is a prognostic factor with a superior weight considering the HR of 3.62, while all the others can be considered prognostic factors with equivalent weight as the HRs are quite similar (HRs between 1.55 and 1.92). Based on these reasons, we developed a prognostic model called the MAGIC‐D index by assigning a score of 2 for metastatic disease, and a score of 1 for CEA increased levels, albumin decreased levels, GGT increased levels, NLR ≥ 3. Patients were stratified into three risk groups as follows: low‐risk group (Score from 0 to 2), intermediate‐risk group (Score from 3 to 4) and high‐risk group (Score from 5 to 6). At the first data cutoff (April 2024), these data were available for 319 patients that composed the training cohort used for the analysis. At the second data cutoff (May 2025), 79 patients were further enrolled and composed the validation cohort.

Results

Median progression‐free survival was 11.7 months in low‐risk group (20.7%), 8.7 months in intermediate‐risk group (46.4%) and 5.4 months in high‐risk group (32.9%) [low‐risk hazard ratio (HR): 0.27, intermediate‐risk HR: 0.55, high‐risk HR: 1, p < 0.0001]. Median OS was 18.4 months in low‐risk group,15.9 months in intermediate‐risk group and 7.8 months in high‐risk group (low‐risk HR: 0.17, intermediate‐risk HR: 0.43, high‐risk HR: 1, p < 0.0001). There was no difference in overall response rate (low‐risk: 31.8%, intermediate‐risk: 36.5% and high‐risk: 25.7%; p = 0.0718), while disease control rate was significantly different across the three risk groups (low‐risk: 83.3%, intermediate‐risk: 70.9% and high‐risk: 60.9%; p < 0.0001) as well as the rate of patients receiving a second‐line therapy (low‐risk: 54.5%, intermediate‐risk: 48.6% and high‐risk: 25.7%; p = 0.0061). Finally, the prognostic role in terms of OS and PFS of the MAGIC‐D index was confirmed in a validation cohort of 79 patients.

Conclusion

The MAGIC‐D index is an easy‐to‐use tool able to stratify patients with BTC with different prognoses undergoing first‐line therapy with CGD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsHumansCisplatinMaleFemaleGemcitabineMiddle AgedAgedPrognosisAntibodies, MonoclonalCarcinoembryonic AntigenAdultgamma-GlutamyltransferaseNeutrophilsRetrospective StudiesNeoplasm Staging

Stichwörter der Autor:innen

biliary tract cancerdurvalumabprognostic index

Substanzen

CisplatinDeoxycytidineGemcitabinedurvalumabAntibodies, MonoclonalCarcinoembryonic Antigengamma-Glutamyltransferase

Autor:innen und Institutionen

  • Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
  • Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
  • Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Department of Translational Research and new Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
  • Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

ORCID-Profile: Mara Persano, Margherita Rimini, Francesca Salani, Jin Won Kim, Salvatore Corallo, Ilario Giovanni Rapposelli, Fabian Finkelmeier, Chiara Pircher, Chiara Pirrone, Florian Castet, Changhoon Yoo, Ester Oneda, Nuno Couto, Jorge Adeva, Giulia Tesini

Zitieren

APA

Persano, M., Rimini, M., Salani, F., Prinzi, F. L., Nichetti, F., Saborowski, A., Antonuzzo, L., Passeri, L., Satake, T., Peeters, F., Vivaldi, C., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Corallo, S., Rapposelli, I. G., Tamberi, S., Finkelmeier, F., …, & Tonini, G. (2025). A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index. Liver International, 45(7). https://doi.org/10.1111/liv.70181

Vancouver

Persano M, Rimini M, Salani F, Prinzi FL, Nichetti F, Saborowski A, et al. A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index. Liver International. 2025;45(7). doi:10.1111/liv.70181

BibTeX
@article{Persano2025,
  author = {Persano, Mara and Rimini, Margherita and Salani, Francesca and Prinzi, Federica Lo and Nichetti, Federico and Saborowski, Anna and Antonuzzo, Lorenzo and Passeri, Laura and Satake, Tomoyuki and Peeters, Frederik and Vivaldi, Caterina and Pressiani, Tiziana and Lucchetti, Jessica and Kim, Jin Won and Abidoye, Oluseyi and Corallo, Salvatore and Rapposelli, Ilario Giovanni and Tamberi, Stefano and Finkelmeier, Fabian and Giordano, Guido and Pircher, Chiara and Chon, Hong Jae and Braconi, Chiara and Qaisar, Aitzaz and Pirrone, Chiara and Castet, Florian and Tamburini, Emiliano and Yoo, Changhoon and Parisi, Alessandro and Diana, Anna and Scartozzi, Mario and Prager, Gerald W and Avallone, Antonio and Schirripa, Marta and Kim, Il Hwan and Perkhofer, Lukas and Oneda, Ester and Verrico, Monica and Couto, Nuno and Adeva, Jorge and Chan, Stephen L and Spinelli, Gian Paolo and Personeni, Nicola and Garajova, Ingrid and Rodriquenz, Maria Grazia and Leo, Silvana and Alvim, Cecilia Melo and Roque, Ricardo and Farinea, Giovanni and Fornaro, Lorenzo and De Rosa, Antonio and Lanzetta, Irene and Balsano, Rita and Lavacchi, Daniele and Camera, Silvia and Ikeda, Masafumi and Dekervel, Jeroen and Niger, Monica and Tesini, Giulia and Tonini, Giuseppe},
  title = {A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {7},
  doi = {10.1111/liv.70181}
}
Kostenlos starten →